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Patients diagnosed with chronic lymphocytic leukemia (CLL) displaya high incidence of infections due to an associated immunodeficien-cy that includes hypogammaglobulinemia. A higher risk of infec-
tions has also been recently reported for high-count monoclonal B-cell
lymphocytosis, while no information is available in low-count mono-
clonal B-cell lymphocytosis. Here, we evaluated the status of the
humoral immune system in patients with chronic lymphocytic leukemia
(n=58), as well as in low- (n=71) and high- (n=29) count monoclonal 
B-cell lymphocytosis versus healthy donors (n=91). Total free plasma
immunoglobulin titers and specific levels of antibodies against
cytomegalovirus, Epstein-Barr virus, influenza and S.pneumoniae were
measured by nephelometry and ELISA-based techniques, respectively.
Overall, our results show that both CLL and high-count monoclonal B-
cell lymphocytosis patients, but not low-count monoclonal B-cell lym-
phocytosis subjects, present with relatively high levels of antibodies spe-
cific for the latent viruses investigated, associated with progressively
lower levels of S.pneumoniae-specific immunoglobulins. These findings
probably reflect asymptomatic chronic reactivation of humoral immune
responses against host viruses associated with expanded virus-specific
antibody levels and progressively decreased protection against other
micro-organisms, denoting a severe humoral immunodeficiency state
not reflected by the overall plasma immunoglobulin levels. Alternatively,
these results could reflect a potential role of ubiquitous viruses in the
pathogenesis of the disease. Further analyses are necessary to establish
the relevance of such asymptomatic humoral immune responses against
host viruses in the expansion of the tumor B-cell clone and progression
from monoclonal B-cell lymphocytosis to CLL.
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ABSTRACT
Introduction
Chronic lymphocytic leukemia (CLL) is the most com-
mon leukemia in adults in Western countries. It is charac-
terized by an expansion of 5×109/L or more clonal 
B lymphocytes in peripheral blood (PB) that co-express
CD5, CD19, CD23 and CD200, together with abnormally
low levels  of CD20, CD22, CD79b and surface
immunoglobulins (sIg).1-4 CLL typically occurs in elderly
patients and has a highly variable clinical course.5 Despite
the heterogeneous clinical outcome, the majority of  CLL
patients share a profound immune dysregulation which is
already detected at the earliest stages of the disease, and
that progressively becomes more severe during clinical
observation, leading to patient death even in the absence
of disease progression.6 The precise mechanisms underly-
ing such immune dysregulation in CLL are not fully under-
stood; however, hypogammaglobulinemia has been iden-
tified as one of the major factors involved,6-8 both in the
immunodeficiency status and death of CLL patients.9,10
Thus, hypogammaglobulinemia is present in up to 85% of
patients. During the course of disease,  a direct association
has been reported between the stage and duration of dis-
ease and the severity of hypogammaglobulinemia.11,12 As a
result, infection is one of the most prevalent causes of
morbidity and mortality in CLL.13 Approximately 80% of
CLL patients have infections during the course of the dis-
ease; such infections particularly involve the respiratory
tract, pneumonia accounting for approximately 75% of all
pulmonary complications in CLL.14
Recent studies have reported that subjects at earlier
stages of the disease [e.g. high-count monoclonal B-cell
lymphocytosis (MBLhi)] also have an increased risk of
infections and a greater rate of infection-related deaths.15
Thus, hospitalization due to infection is significantly more
common among MBLhi cases than in the general popula-
tion (16% vs. 2.6% after a median follow-up period of 10
years, respectively), the overall frequency of infection in
MBLhi individuals being similar to that of newly-diagnosed
CLL patients (18%).15 Since vaccination represents an
effective strategy to decrease the risk of infection in
immunocompromised patients, the potential definition of
optimal vaccination strategies in MBLhi and CLL requires a
more in depth and comprehensive understanding of the
dysregulated immunological mechanisms in these
patients.
In order to gain further insight into the nature, relevance
and clinical significance of hypogammaglobulinemia in
CLL and MBL patients, we evaluated the soluble levels of
plasma antibodies specific for ubiquitous pulmonary
infection-associated pathogens (i.e. influenza A and B
viruses and S.pneumoniae) as well as other ubiquitous host
pathogens, such as cytomegalovirus (CMV) and Epstein-
Barr virus (EBV), in newly-diagnosed untreated CLL
patients  at different stages of the disease (Binet A vs. Binet
B/C), pre-leukemic MBLhi, and low-count MBL (MBLlo)
subjects versus a large group of age- and sex-matched
healthy individuals from the same geographical area.
Methods
Controls and patients
A total of 249 individuals were prospectively studied between
November 2007 to November 2012. These subjects were classified
into four subgroups: healthy donors (controls; n=91), CLL-like
MBLlo (n=71), CLL-like MBLhi (n=29), and newly-diagnosed previ-
ously untreated CLL patients (n=58). According to the World
Health Organization (WHO) 2016 criteria,16 MBL was diagnosed
whenever less than 5x109/L clonal B cells with a CLL phenotype
were present in PB, in the absence of other signs of disease; other-
wise, diagnosis of CLL was established. Within CLL, 32 patients
were classified as early stage CLL (Binet A), while the remaining
26 corresponded to advanced-stage CLL (Binet B/C).4 In turn,
MBLlo and MBLhi cases were discriminated based on a cut-off value
of less than 0.5x109/L circulating clonal B cells with CLL-like phe-
notype, as described elsewhere.17 Additional information about
the inclusion and exclusion criteria for selection of controls and
patients, as well as procedures for sample collection and storage
are detailed in the Online Supplementary Methods. The study was
approved by the local Ethics Committee of the University
Hospital of Salamanca, and conducted in accordance with the
Declaration of Helsinki.
Immunophenotypic studies
Immunophenotypic studies were performed on erythrocyte-
lyzed PB samples, using a high-sensitive multicolor flow cytome-
try approach, previously described in detail.18 For this purpose, PB
white blood cells (WBC) were systematically stained with the
monoclonal antibody (MAb) combinations detailed in Online
Supplementary Table S1. For flow cytometry data analysis, the
INFINICYTTM software (Cytognos S.L., Salamanca, Spain) was
used. All cases showed a clonal-imbalanced surface membrane
(Sm) immunoglobulin (Ig)-kappa : SmIg-lambda ratio of >3:1 or
<1:319and/or an aberrant CD5+ CLL(-like)  B-cell population. The
minimum number of clustered events required to define an abnor-
mal B-cell population was  50 cells or more.
Measurement of soluble plasma levels of anti-viral and
streptococcus pneumoniae (pneumococcus)-specific
antibodies
Exposure to CMV, EBV, influenza A and B viruses, and pneumo-
coccus were measured by immunoenzymatic-based approaches,
including either enzyme-linked immunosorbent (ELISA) or chemi-
luminescent immune assays, using commercially available kits, as
detailed in the Online Supplementary Methods and Online
Supplementary Table S2. Of note, analysis of influenza A- and
influenza B-specific IgM and IgG and S.pneumoniae-specific IgG
plasma levels was restricted to those subjects who had not been
vaccinated against influenza and S.pneumoniae, respectively, during
the 9-year period prior to the study (Online Supplementary
Methods). In each patient, total plasma levels of IgM, IgG and IgA
were systematically measured in parallel by nephelometry. 
Quantitation of CMV and EBV viral copy number in
plasma
Detection and quantitation of CMV and EBV viral load in plas-
ma was determined in a subset of 177 and 191 subjects, respective-
ly, using commercially available kits:
COBAS®AMPLiPrep/COBAS®TaqMan (Roche Diagnostics, Basel,
Switzerland) and EBV R-gene® (BioMerieux, Verniolle, France),
with strict adherence to the  manufacturers’ instructions. 
Results
Clinical and laboratory features of MBL versus CLL
patients
Overall, 249 individuals, including 119 males (48%) and
130 females (52%), with a mean age of 68±11 years were
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studied; there was a similar distribution according to  age
across the different patient groups and controls.
Interestingly, while females predominated among MBLlo
cases (male/female ratio 1:2), MBLhi and CLL showed a
significantly (P<0.01) higher male/female ratio (5:1 and
1.2:1, respectively) (Table 1). As expected, abnormal blood
cell counts were found only in MBLhi and CLL patients
(but not in MBLlo), including lower platelet counts and
hemoglobin levels among stage B/C CLL. Likewise, the
absolute number of PB clonal B cells/μl progressively
increased from MBLlo subjects to advanced-stage CLL
patients (P<0.05). CLL patients also showed a greater fre-
quency of IGHV unmutated cases (from 20% in MBLlo to
26% in MBLhi, 41% in CLL stage A and 64% in CLL stage
B/C; P=0.04), whereas MBLlo cases showed a significantly
lower frequency of cytogenetically altered CLL-like clones
compared to both MBLhi and CLL (30% vs. 68% and 70%,
respectively; P=0.002) (Table 1). Of note, all subjects were
from the same geographical area (Province of Salamanca,
Northwest-Central Spain) and, therefore, shared a similar
antigen environment. 
Soluble Ig plasma levels in MBL and CLL versus
healthy controls
Whereas total Ig plasma levels were within the normal
range in MBLlo cases, they were significantly decreased in
MBLhi and CLL patients versus both controls and MBLlo
cases (Figure 1A). Interestingly, progressively lower levels
of total plasma Igs were found from MBLhi to stage A and
stage B/C CLL cases, the latter two groups showing signif-
icantly lower amounts of plasma Igs versus MBLhi cases
(P=0.04 for stage A and P=0.02 for stage B/C) (Figure 1A).
In more detail, none of the MBLlo subjects presented with
decreased total Ig plasma levels below the normal range,
while the frequency of hypogammaglobulinemia
increased from MBLhi to early- and advanced-stage CLL
patients: 7% versus 16% and 19%, respectively (P<0.001)
(Figure 1A). Of note, progressively lower levels of plasma
Igs were observed from MBLhi to advanced stage CLL also
for each Ig isotype  (Figure 1B, C and D), particularly for
IgM and IgA. Thus, all except one MBLlo case showed nor-
mal amounts of IgM, IgG and IgA plasma levels; in con-
trast, 17% of MBLhi subjects, 38% stage A CLL and 46%
stage B/C CLL patients had decreased amounts of plasma
IgM (P<0.0001). In addition, 10% of MBLhi cases had
decreased IgA plasma levels versus 16% of stage A CLL
and 46% of stage B/C CLL patients (P<0.0001); in turn,
IgG plasma levels were decreased in 14% of MBLhi cases
and 24% of CLL patients (P>0.05) versus none of the MBLlo
subjects.
CMV-, EBV- and influenza-specific IgM and IgG plasma
levels in MBL and CLL patients versus healthy controls
As expected for a Mediterranean country, more than
90% of adults analyzed here had been exposed to both
CMV and EBV before sample collection, regardless of the
I. Criado et al.
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Table 1. Clinical and laboratory characteristics of controls versus monoclonal B-cell lymphocytosis subjects and chronic lymphocytic leukemia
patients.
Healthy MBLlo MBLhi CLL CLL CLL P
donors (n=91) (n=79) (n=29) Stage A Stage B/C (n=58)
(n=32) (n=26)
Age (years) 70 72 68 67 70 68 NS
(43-87) (43-95) (52-85) (45-85) (41-85) (41-85)
Sex (M/F) 42% / 58% 35% / 65% 83% / 17% 56% / 44% 54% / 46% 55% / 45% P<0.01b
Hemoglobin (g/L) 147 144 144 145 118 136 P<0.01a
(106-181) (99-177) (130-190) (120-174) (88-164) (88-174)
N. of platelets x109/L 226 222 198 211 137 174 P<0.01a
(90-388) (119-262) (85-386) (112-408) (67-271) (67-408)
N. of leukocytes/μl 6,200 6,090 11,550 27,310 53,880 34,920 P<0.01ab
(3550-11,240) (3650-9400) (7154-15,660) (13,520-393,530) (16,630-289,420) (13,520-393,530)
N. of lymphocytes/μl 1678 1774 5250 18,591 50,346 25.939 P<0.01ab
(766-4124) (317-3749) (2291-9333) (6469-381,409) (12,779-282,098) (6469-381,409)
N. of B lymphocytes/μl 138 139 3.097 17,727 41.493 21.352 P<0.01ab
(31-776) (31-478) (978-4773) (5134-369,288) (8176-276,367) (5134-369,288)
N. of clonal B NA 0.731 3.035 17.686 41.442 21.130 P<0.01ab
lymphocytes/μl (0024-82.24) (921-4844) (5065-369,288) (8019-276,367) (5065-369,288)
Mutational status (Mut/UMut) NA *80%/20% 74%/26% 59%/41% 36%/64% 49%/51% P<0.05c
Cytogenetic alterations
% cases altered NA *30% 68% 69% 71% 70% P<0.01c
% cases del13q14(D13S25) NA *30% 39% 50% 39% 45% NS
% cases trisomy cr. 12 NA *6% 25% 6% 33% 18% NS
% cases del11q22(ATM) NA *0% 7% 13% 13% 13% NS
% cases del17p13(TP53) NA *0% 0% 0% 0% 0% NS
Results expressed either as median (range) or as percentage of cases for continuous and categorical variables, respectively.  The CLL group includes both CLL Binet stage A and
CLL Stage B/C cases. aCLL versus all other groups. bMBLhi versus all other groups. cCLL versus healthy individuals. CLL: chronic lymphocytic leukemia; F: female; M: male; MBLhi:
high-count monoclonal B lymphocytosis; MBLlo: low-count monoclonal B lymphocytosis; Mut: mutated; NA: not applicable; ND: not determined; NS: no statistically significant dif-
ferences detected (P>0.05); Umut: unmutated. *Sample size restricted to 23 subjects in which molecular and cytogenetic determinations were performed.
diagnostic subgroup (Online Supplementary Table S3). In vir-
tually every case the pattern of plasma antibodies specific
for both viruses was consistent with past infection (i.e.
CMV- or EBV-specific IgG-positive and IgM-negative plas-
ma antibodies). In contrast, variable percentages of cases
from the different study groups showed influenza virus-
specific plasma Igs for the strains evaluated (Online
Supplementary Table S3); in most of these cases, the pattern
observed also corresponded to past exposure to the virus-
es. From the whole series of subjects who showed influen-
za virus-specific plasma Igs (n=127), 36 reported that they
had been vaccinated against influenza virus before their
recruitment; no statistically significant differences were
observed in the distribution of these subjects in the dis-
tinct groups of individuals under study (Online
Supplementary Table S3). Those patients found to have
been previously exposed to any of the viruses investigated
(i.e. those who showed increased plasma levels of at least
one of the virus-specific Ig tested) were further evaluated
for the corresponding pathogen-specific Ig plasma levels.
Overall, plasma levels of pathogen-specific IgM and IgG
antibodies did not follow the pattern observed for total
IgM and IgG plasma levels in the different groups of sub-
jects analyzed (Figure 1). Thus, there was no reduction of
specific IgM and IgG against CMV, EBV viral capside anti-
gen (VCA) and influenza A and B in MBLhi and even in
CLL patients versus both controls and MBLlo (Online
Supplementary Figure S1). Regarding CMV-specific IgM and
IgG titers and the amount of plasma IgM antibodies
against VCA-EBV and the influenza virus, no significant
differences were actually observed among individuals of
the different groups studied (e.g. controls, MBLhi and CLL)
(Online Supplementary Figure S1A, C and F).  In contrast,
VCA-EBV-specific IgG plasma levels were higher (P=0.01)
in CLL patients versus both controls and MBLlo cases
(Online Supplementary Figure S1D). However, clear differ-
ences emerged (or they increased) when the ratio between
the plasma levels of each of these pathogen-specific IgG
antibodies (CMV-, VCA-EBV- and influenza-specific IgG)
plasma levels and the overall amount of plasma IgG per
subject/patient was considered (Figure 2). Thereby, the
CMV-specific IgM/total IgM and CMV-, VCA-EBV-specif-
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Figure 1. Soluble immunoglobulin immunoglobulin (Ig) plasma levels in monoclonal B lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) versus
healthy donors. (A)  The overall amount of plasma immunoglobulins (md/dl) determined by conventional nephelometry is shown for the different groups of individ-
uals analyzed. (B-D)  IgM, IgG and IgA plasma levels within the different groups of individuals studied, respectively. Notched boxes represent 25th and 75th percentile
values; the lines in the middle correspond to median values (50th percentile) and vertical lines represent the highest and lowest values that are neither outliers nor
extreme values. Vertical dotted lines represent the inferior limit value of normality for each immunoglobulin. Dotted lines represent the lower limit of normality for
each immunoglobulin (40 mg/dl; 700 mg/dl; and 70 mg/dl). Numbers under dotted lines represent the percentage of cases with plasma levels of the corresponding
immunoglobulin found to be below normal values. *P<0.05 versus healthy donors and MBLlo; **P<0.05  versus healthy donors, MBLlo and MBLhi.  MBLhi: high-count





ic IgG/total IgG ratios were significantly higher in CLL
(P≤0.001), particularly in stage B/C CLL cases (P≤0.02) 
versus healthy donors and MBLlo subjects. Likewise, the
influenza-specific IgG/total IgG ratio tended to be higher
(P=0.056) for CLL patients compared to healthy donors
and MBLlo cases (Figure 2). Of note, MBLhi also showed sig-
nificantly higher anti-VCA-EBV-specific IgG/total IgG
plasma levels than controls and MBLlo cases (Figure 2D).
An exception to this general pattern was the EBNA-specif-
ic IgG plasma levels, which were found to be significantly
reduced (vs. healthy donors) in both MBLhi (P=0.01) and
CLL patients (P=0.002), particularly in stage B/C CLL
(P=0.002) (Online Supplementary Figure S1E).
S.Pneumoniae-specific IgG plasma levels in MBL and
CLL versus healthy controls
As mentioned above, S.pneumoniae-specific IgG plasma
levels were quantified in those subjects who reported no
previous administration of anti-PCP (Pneumococcal
Capsular Polysaccharide) vaccination (Figure 3). Their
amount, as well as the pathogen specific IgG/total IgG
ratio were within the normal range in all MBLlo subjects
and healthy controls analyzed (Figure 3A and 3).
However, S.pneumoniae-specific IgG plasma levels were
significantly reduced in MBLhi and CLL patients versus
both controls and MBLlo (Figure 3A), in contrast to what
was observed for virtually all viral pathogens described
above, except the EBNA-specific IgG antibodies.
Interestingly, no statistically significant differences were
observed between MBLhi and CLL as regards the overall
amount of anti-S.pneumoniae-specific IgG plasma levels.
Of note, the ratio between the anti-S.pneumoniae-specific
IgG and total IgG plasma levels was similar among the dis-
tinct groups of subjects analyzed (Figure 3B), as both the
S.pneumoniae-specific IgG and the overall IgG plasma lev-
els directly correlated within each group of subjects ana-
lyzed.
CMV and EBV viral load and virus-specific Ig titers
Overall, viral load for CMV was studied in plasma from
177 subjects (53 controls, 56 MBLlo, 22 MBLhi and 46 CLL
patients). No viral DNA was detected in any sample
except 3 cases (1 MBLhiand 2 CLL Binet A subjects), in
which the viral load could not be precisely quantified, as
I. Criado et al.
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Figure 2. Ratio between pathogen-specific immunoglobulin (Ig) plasma levels and total immunoglobulin plasma levels per Ig isotype in monoclonal B lymphocy-
tosis (MBL) and chronic lymphocytic leukemia (CLL) patients versus healthy subjects. (A and B) Ratio between cytomegalovirus (CMV)-specific IgM and IgG plasma
titers and the overall plasma IgM and IgG levels, respectively. (C and D) Ratio between viral capside antigen (VCA)-Epstein-Barr virus (EBV)-specific IgM and IgG titers
in plasma and the overall amount of IgM and IgG in plasma, respectively. (E) Anti Epstein-Barr nuclear antigen (EBNA)-EBV-specific IgG/total IgG plasma level ratio.
(F and G) Influenza (strains A + B)-specific/total IgM and IgG ratios, respectively. Only data on seropositive subjects for each pathogen are included in this figure. (F
and G)  Data presented correspond only to subjects who referred no previous vaccination against influenza. Notched boxes represent 25th and 75th percentile values;
the lines in the middle correspond to median values (50th percentile), whereas vertical lines represent the highest and lowest values that are neither outliers nor








it was below the limit of quantification of the method
(<137 IU/ml).  In turn, EBV DNA load (measured in 191
samples: 57 controls, 59 MBLlo, 23 MBLhi, 53 CLL patients)
was detected in plasma from 7 of 53 Binet A CLL patients
(13%), while systematically undetectable in the other
three groups (P<0.0001). No statistically significant differ-
ences in gender distribution, age, number of clonal B cells
and EBV (VCA)-specific IgM and IgG titers were found
between CLL cases with quantifiable EBV DNA in plasma
versus negative CLL cases. Also, no statistical correlation
was found between the number of EBV DNA copies
(median of 3.6 DNA copies/μl; range 1.4-22.8 DNA
copies/μl) and EBV-specifc immunoglobulin titers in plas-
ma for those 7 EBV-viral load-positive CLL cases.
Discussion 
Infection is one of the most frequent causes of death in
CLL (approx. 30-50% of CLL patients).8 Although the spe-
cific mechanisms underlying immune dysregulation in
CLL are not fully understood8, hypogammaglobulinemia,
together with T-cell abnormalities, are common features
of the CLL-associated immunodeficiency status, the for-
mer affecting up to 85% of the patients already at diagno-
sis or during the course of their disease.9,10 The frequency
and severity of hypogammaglobulinemia (at the expense
of all major Ig isotypes) increase from MBL subjects to
early and advanced stage CLL patients. Here, we confirm
and extend on these observations.  Thus, we show for the
first time that total soluble Ig plasma levels are within nor-
mal values in MBLlo subjects, regardless of the Ig isotype
evaluated; in contrast, hypogammaglobulinemia was a rel-
atively frequent feature of MBLhi cases. Of note, the degree
of decreased IgM and IgG plasma levels in MBLhi was sim-
ilar to that observed in stage A CLL. In a recent study,
Glancy et al. have even reported a higher frequency of
decreased IgG levels in MBLhi (i.e. 7 of 24 MBLhi cases,
which represents a frequency of IgG hypogammaglobu-
linemia of 29%20 vs. 14% in our series). This apparent dis-
crepancy might be due to the fact that our series mostly
comprised MBLhi cases with lower numbers of clonal B
cells studied at diagnosis, while 4 of 7 MBLhi cases report-
ed by Glancy et al. to have low IgG titers, had absolute
lymphocyte counts more than 4x109/L. Nevertheless, it
should be noted that we did not find any correlation
between soluble Ig plasma levels and the number of clonal
B cells in PB, within each group of subjects analyzed (data
not shown). In contrast, a statistically significant direct cor-
relation was found between total Ig plasma levels and the
number of normal residual B cells among CLL patients
(r=0.29, P=0.04). Therefore, presence of hypogammaglob-
ulinemia in MBLhi cases could also reflect a defective nor-
mal residual B-cell function and it might contribute to
explain the near 3-fold increased frequency of infection
observed among these subjects versus the general popula-
tion of the same age and having the same comorbidities,
to that of newly-diagnosed CLL.15 Altogether, these find-
ings suggest that antibody-related immunodeficiency
might emerge before the onset of CLL, already at an MBLhi
state, preceding (or potentially favoring) malignant trans-
formation and progression of the disease.
Despite a progressive reduction of (total) soluble Ig plas-
ma levels from MBL to advanced CLL, similar levels of
CMV-specific IgM and IgG, VCA-EBV-specific IgM and
influenza-specific IgM and IgG were found among the five
groups analyzed (i.e. healthy donors, MBLlo, MBLhi, early
CLL and advanced stage CLL). Indeed, VCA-EBV-specific
IgG levels were even increased in CLL patients versus
healthy subjects. Furthermore, when the ratio between
each of these Ab levels and the total plasma levels of the
corresponding Ig isotype (IgM or IgG) were considered,
progressively greater fractions of the above referred anti-
gen-specific antibodies per-isotype were found from
MBLhi to stage A and stage B/C CLL patients, respectively.
Our findings on the antibody levels against CMV confirm
previous results on CLL reported by Vanura et al. who also
showed that, despite progressive decay of total IgM and
Pathogen-specific antibodies in MBL and CLL
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Figure 3. Streptococcus pneumoniae-specific IgG plasma levels in monoclonal B lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) patients  versus
healthy controls.  (A) Titers of antibody-specific plasma levels against the pneumococcal polysaccharide antigen for each group of individuals analyzed. (B) Ratio
between anti-pneumococcus-specific IgG and total IgG plasma levels for each group of subjects investigated. Only data from those subjects that did not receive vac-
cination against S.pneumoniae are displayed. Notched boxes represent 25th and 75th percentile values; the lines in the middle correspond to median values (50th
percentile), while vertical lines represent the highest and lowest values that are neither outliers nor extreme values. *P<0.05 versus healthy donors and MBLlo. MBLhi:
high-count monoclonal B lymphocytosis; MBLlo: low-count monoclonal B lymphocytosis.
A B
IgG subclasses, the CMV-specific immune response may
be preserved even in CLL cases with advanced disease.21
Here, we confirm and extend on these findings by show-
ing for the first time that: i) this behavior is already
detectable at the MBLhi stage; and ii) it is also common to
other antibody responses against EBV and the influenza
virus in non-vaccinated individuals, despite the mecha-
nisms by which influenza infects cells are completely dif-
ferent from those of CMV and EBV.22-24 As mentioned
above, we did observe decreased titers of EBV-specific IgG
levels in both MBLhi and CLL; interestingly, this was
restricted to the antibody response against the EBNA-EBV
antigen, but not the VCA-EBV antigen. The EBNA-EBV
protein is located in the nucleus of infected host cells and
it acts as a transcription factor for the virus, allowing for
its replication inside the cell;23 in contrast, the VCA-EBV
protein is a structural component of the capside of the
virus.25 Therefore, the (humoral) immune response against
the VCA-antigen might only occur if infected cells are
lysed and active viral replications occurs. Therefore, our
results  suggest that like CMV, EBV probably undergoes a
mild (undetectable) reactivation, whenever an immunode-
ficiency state has been acquired, but fully bloomed EBV
and CMV infections can still be controlled, as reflected by
the preserved production of specific antibodies against
both viruses in MBLhi and CLL patients21 and the detection
of quantifiable EBV DNA in plasma of CLL cases but not
MBL. Long-term monitoring of virus-specific Ig plasma
levels in CLL versus MBL versus healthy donors is required
to validate this hypothesis.
In contrast to the general pattern found for the plasma
levels of antibodies against the ubiquitous viruses here
investigated, a significant reduction was observed in the
plasma levels of pneumococcus-specific IgG from MBLhi to
stage B/C CLL, in parallel to the overall decrease in total
IgG plasma levels. These findings further suggest that,
while the antibody-mediated immune response against
ubiquitous pathogens (e.g. human herpesviruses and
influenza virus) is still preserved and the virus is actively
controlled in immunocompromised MBLhi and CLL
patients, protection against other pathogens (i.e. pneumo-
coccus) is progressively lost, placing these patients at risk
of severe infection and death.  In line with this hypothesis,
CMV disease is infrequent among untreated CLL patients
compared to other immunocompromised patients.13,26 In
contrast, CLL patients frequently present respiratory tract
infections caused by encapsulated bacteria, particularly
Streptococcus pneumoniae and Haemophilus influenza,27 fur-
ther supporting a unique dysregulation of immunesurveil-
lance against infectious agents in MBLhi and CLL.
To the best of our knowledge, no studies have been
reported so far about the immune response profile against
different pathogens in MBLlo subjects. As no differences
were detected in both total and pathogen specific Ig plas-
ma titers in MBLlo versus age-matched healthy subjects of
the same geographical area, it might be expected that the
antibody response of these subjects remains normal or at
most little altered. Altogether, these findings suggest that
the onset of dysregulated antibody-based immune
responses might occur in the transition from MBLlo to
MBLhi and CLL, being associated with a clinically silent
reactivation of preserved T-cell dependent antibody
responses against host viruses. If this holds true, and
chronic baseline activation of antibody responses against
host viruses occurs in MBLhi and CLL patients, such a
response could also potentially affect the tumor clone and
contribute to its expansion and progression of the disease.
In line with this hypothesis, it has been shown that most
MBLlo subjects show (oligoclonal) expansions of
CD4+/CD8+ double-positive T cells28 which have a limited
TCRvβ repertoire and participate in immune responses
against chronic viral infections, particularly against CMV.29
There is even stronger  evidence to suggest that CLL
evolves from repetitive activation of particular B-cell
clones through B-cell receptor (BCR) triggering by conven-
tional antigens,30 which, in the light of the results  reported
here, increase in the CMV- and EBV-specific IgG/total Ig
ratio in both MBLhi and CLL patients. This might further
suggest a potential role for ubiquitous viruses in the patho-
genesis of the disease. Previous findings showing an asso-
ciation between the presence of CMV- and EBV-DNA in
blood of CLL patients who express stereotyped IGHV4-34
BCRs31 would further support this hypothesis. However,
here we only analyzed a relatively limited number of cases
within each study group, particularly within the MBLhi
group, and, therefore, further long-term longitudinal stud-
ies in MBL and CLL in larger series of subjects are neces-
sary in order to elucidate the value of (total and pathogen-
specific) Ig plasma levels, as a surrogate marker for a nor-
mal versus abnormal B-cell function, and to determine both
the risk of progression from MBL to CLL and the potential
need for adoption of specific active immunotherapy meas-
ures for patients at risk of life-threatening infections. In
this regard, extensive research on the effectiveness of vac-
cines, particularly against influenza and S.pneumoniae, has
been carried out in CLL, while there is limited information
on MBLhi.15 Thus, response to vaccination against both
polysaccharide (e.g. classical multivalent pneumococcal
vaccines32,33) and protein antigens (e.g. tetanus toxoid and
influenza virus34,35) has been shown to be associated with
poor seroprotective responses in CLL, even after various
doses. Such defective antibody responses have been relat-
ed to a broad variety of immune defects including comple-
ment dysregulation, 
T-cell impaired function and altered antigen presentation,
in addition to B-cell deficiency.8,9,27,36,37 Because of this, vac-
cination of CLL patients early after diagnosis, and particu-
larly even at the MBL stage when better responses might
be expected,8,33 has been proposed as a potentially effec-
tive strategy to improve serological immune protection of
CLL patients against the most common pathogens. Parallel
analyses focused on the humoral immunity and immune
responses other than just the evaluation of plasma anti-
body levels are required to fully understand the unique-
ness of the immunodeficiency status of MBLhi and CLL
patients.
In summary, we report on the existence of a significant
and selective, defective antibody protection against
S.pneumoniae in CLL which emerges already among MBLhi
to early stage CLL and worsens through progression of the
disease. Such an  immune defect might be associated with
an active, but silent, response against host viruses such as
CMV, EBV and influenza, for which preserved antibody
serum levels are detected, even in advanced CLL. These
results suggest that chronic viral re-activation might con-
tribute to the preserved host virus-specific antibody titers
through sustained immune responses, which might also
favor parallel expansion of the tumor B-cell clone and pro-
gression from MBLhi to CLL. Further studies in larger MBL
and CLL patient cohorts with long-term follow up and
I. Criado et al.
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sequential serological analyses are necessary to confirm
this hypothesis.
Primary Health Care Group of Salamanca for the study of
MBL: list of members (alphabetical order): Alonso Martín,
María Monserrat (C.S. Fuentes de Oñoro); Asensio Oliva,
María Carmen (C.S. Santa Marta de Tormes), Bárez
Hernández, Pilar (C.S. Garrido Sur); Cabo Sastre, Luis (C.S.
Ledesma); Carreño Luengo, María Teresa (C.S. Ledesma);
Casado Romo, José María (C.S. Alba de Tormes); Cubino Luis,
Rocio (C.S. Sancti Spiritus); De Vega Parra, José (C.S.
Peñaranda); Franco Esteban, Eloy (C.S. Pizarrales-Vidal);
García García, María Concepción (C.S. Guijuelo); García
Rodríguez, Bernardo Lucio (C.S. La Alberca); Garzón Martín,
Agustín (C.S. Peñaranda); Goenaga Andrés, Rosario (C.S.
Ledesma); Gómez Cabrera, Rosalia (C.S. Garrido Sur); Gómez
Sánchez, Francisco (C.S. Periurbana Norte); González Moreno,
Josefa (C.S. Guijuelo); González Vicente, Ángel Carlos (C.S.
Aldeadávila de la Ribera); Guarido Mateos, José Manuel (C.S.
Vitigudino); Hernández Sánchez, María Jesús (C.S. Vitigudino);
Herraes Martín, Ricardo (C.S. La Alberca); Herrero Sánchez,
Amparo (C.S. Fuentes de Oñoro); Jiménez Ruano, María Josefa
(C.S. Garrido Norte); Jimeno Cascón, Teresa Basa (C.S. Elena
Ginel Díez); Macías Kuhn, Francisco (C.S. Ledesma); Mateos
Rubio, Pablo (C.S. Ledesma); Márquez Velasco, María Salud
(C.S. Sancti Spiritus); Merino Palazuelo, Miguel (C.S. Fuentes
de Oñoro); Miguel Lozano, Rubén (C.S. Garrido Norte);
Montero Luengo, Juan (C.S. San Juan); Muriel Díaz, María
Paz (C.S. Miguel Armijo); Pablos Regueiro, Araceli (C.S.
Vitigudino); Pascual Martín, J. Antonio (C.S. Fuentes de Oñoro);
Pastor Alcalá, Luis (C.S. Vitigudino); Pedraza García, Jesús
(C.S. Vitigudino); Pérez Díaz, Manuel (C.S. Pizarrales-Vidal);
Pérez García, Manuel (C.S. Alba de Tormes); Prieto Gutiérrez,
María Teresa (C.S. Peñaranda); Ramos Arranz, Manuel (C.S.
Ledesma); Ramos Mongue, Aurora Esther (C.S. Ledesma);
Rodríguez Medina, Ana María (C.S. Alba de Tormes);
Rodríguez Vegas, Margarita (C.S. Ledesma); Romo Cortina,
Javier (C.S. Elena Ginel Díez); Roselló Carmen, Elena (C.S.
Vitigudino); Sánchez Alonso, Begoña (C.S. Aldeadávila de la
Ribera); Sánchez Bazo, Begoña (C.S. Aldeadávila de la Ribera),
Sánchez White, Nicolás (C.S. Sancti Spiritus); Sandín Pérez,
Rafael (C.S. San José); Sanz Santa-Cruz; Fernando (C.S.
Capuchinos); Soto Jiménez, Francisco (C.S. Santa Marta de
Tormes); Velasco Marcos, María Auxiliadora (C.S. Elena Ginel
Díez); Vicente López, Horacio Marcos (C.S. Aldeadávila de la
Ribera); Vicente Santos, M. Sebastián (C.S. Aldeadávila de la
Ribera).
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